Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048825 · ClinicalTrials.gov registry record · Phase 3
Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry
A Phase 3 study, sponsored by Population Health Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,264
- Enrollment target
NCT03048825: Completed Phase 3 study, sponsored by Population Health Research Institute.
NCT03048825 is a Phase 3 study that has completed, run by Population Health Research Institute. The registered enrollment target is 7,264 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (841% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03048825, a Phase 3 study, has completed, sponsored by Population Health Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,264 participants
- Enrollment target
Study Summary
The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).
Primary Outcome
Major Adverse Cardiac Events (MACE) for SYNERGY Stent (defined as the composite of death, recurrent target vessel MI, stroke, or ischemia driven target vessel revascularization) compared to performance goal
Interventions
- DRUG Spironolactone
- DRUG Colchicine
- DRUG Colchicine-Placebo
- DEVICE SYNERGY Bioabsorbable Polymer Drug-Eluting Stent
- DRUG Spironolactone-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,264 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2024-08-09 |
| Phase | Phase 3 |
What the finished NCT03048825 record still lists
NCT03048825 is an interventional study that assigns participants to a tested intervention. Its 7,264 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (841% higher).
The record links to 0 conditions, and to 5 interventions - of which Spironolactone is the first listed.
NCT03048825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03048825 about?
NCT03048825 is a clinical study titled "Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry". The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).
What is the current status of trial NCT03048825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,264 participants. The study started on 2018-02-01. Estimated completion is 2024-08-09.
What interventions are being tested in trial NCT03048825?
The interventions under investigation include: Spironolactone (DRUG), Colchicine (DRUG), Colchicine-Placebo (DRUG), SYNERGY Bioabsorbable Polymer Drug-Eluting Stent (DEVICE), Spironolactone-Placebo (DRUG).
Who is sponsoring clinical trial NCT03048825?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03048825's enrollment target sits among peer trials
7,264 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI